Trial
NCT02892201
Pembrolizumab in HNSCC With Residual Disease After Radiation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Merck Sharp & Dohme LLC
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Pembrolizumab
Why stopped
Low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-29